Aminoglycoside-related nephrotoxicity in the premature newborn.
The nephrotoxicity of gentamicin and amikacin was compared during presumed sepsis in 107 premature neonates. To examine the possibility that nephrotoxicity was directly associated with the clinical conditions of "sepsis," a control group of 26 chloramphenicol-treated newborns was also studied. Two markers of proximal renal tubular injury, N-acetyl-beta-glucosaminidase (NAG) and beta 2-microglobulin, were measured in 6-hr aliquots of urine. Because urine creatinine excretion increased with postconception age, markers were expressed in terms of excretion rate rather than per milligram of creatinine. The NAG excretion rate was significantly higher in gentamicin-treated patients (138 +/- 10 U/min, mean +/- SE) than in amikacin-treated patients (85 +/- 7 U/min) but did not differ between patients treated with amikacin and those treated with chloramphenicol (81 +/- 11 U/min). Excretion of beta 2-microglobulin did not differ among the three patient groups. We conclude that amikacin may be less nephrotoxic than gentamicin in the premature newborn.
D000118:Acetylglucosaminidase / Q000652:urine; D000583:Amikacin / Q000009:adverse effects* / Q000627:therapeutic use; D002701:Chloramphenicol / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D005839:Gentamicins / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007612:Kanamycin / Q000031:analogs & derivatives*; D007674:Kidney Diseases / Q000139:chemically induced*; D011446:Prospective Studies; D011897:Random Allocation; D018805:Sepsis / Q000188:drug therapy*; D001613:beta 2-Microglobulin / Q000652:urine
D005839:Gentamicins; D001613:beta 2-Microglobulin; D007612:Kanamycin; D002701:Chloramphenicol; D000583:Amikacin; D003404:Creatinine; D000118:Acetylglucosaminidase